Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
about
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.Adaptive metabolic rewiring to chronic SFK inhibitionA case report of tongue metastasis from lung squamous cell carcinoma and literature review.
P2860
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
@en
type
label
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
@en
prefLabel
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
@en
P2860
P356
P1476
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
@en
P2093
Caio M Rocha-Lima
Soley Bayraktar
P2860
P356
10.5306/WJCO.V4.I2.29
P577
2013-05-01T00:00:00Z